

COVID-19 risk and mortality in hospitals: this is not a time to let our guard down

Jemima T Collins ,¹ Ben Carter,² Jonathan Hewitt³

Commenting on

The burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults.

Nosocomial infections are not a new entity. Prior to COVID-19, the prevalence of healthcare-associated infection in the developed world was 4%–7.1%.¹

The pandemic brought hospital admissions to the forefront of public awareness. Who should be admitted to hospital, and who should stay at home? Emergency admissions significantly dropped, for fear of being exposed to the virus. This risk was real, as the earliest reports showed that the rate of COVID-19 acquired in hospital in all inpatients with the disease was as high as 12%.²

In this issue, Ponsford and colleagues³ report outcomes of 2508 patients with COVID-19 in multiple Welsh hospitals during the first wave, based on likelihood of source of exposure. Although the majority of all cases acquired infection in the community, a significant proportion obtained it in hospital—and these people were more likely to have frailty and were hospitalised for weeks prior to being infected.

They showed that inpatient mortality is higher for those with nosocomial infection, than for those who acquire it in the community. The authors provide a clinical outcome ‘sliding scale’ based on likely source of exposure, stating that the source is indeterminate if one tests positive between 2 and 14 days from admission, reflected in differing public health case definitions. Ponsford *et al*⁴ compare their findings with Carter *et al*⁵ and report similar findings. Debate over the definition of nosocomial COVID-19 throughout the UK has continued to offer

uncertainty, with approximately 21% of UK NHS Trust cases ‘probably’ infected while in hospital.⁵

There may be many reasons for these statistics. A complex mode of transmission in hospital is due to uneven super-spreading, where some individuals appear to be significantly more likely to transmit infection than others.⁶ Early in the first wave, appropriate personal protective equipment (PPE) uncertainty and shortages, prolonged lead times for testing of SARS-CoV-2, and presymptomatic healthcare workers may all have contributed to nosocomial infection, despite non-pharmaceutical interventions.

The impact of nosocomial transmission must not be underestimated. This paper as well as others^{3 4 7 8} highlight that those who acquire the infection in hospital are older and frailer. If these patients survive to discharge, they are more likely to have increasing care needs.⁹ Onward community transmission of the infection from nosocomial cases may also have led to a substantial number of subsequent admissions.¹⁰

Recognition of this huge toll, and deficiencies in the infection-control armoury, has increased determination to address these issues. For example, it is now common practice for routine and frequent testing of asymptomatic patients and staff in hospitals. As the pandemic has evolved, so too has understanding of SARS-CoV-2 transmission. Virus particles can be airborne and linger for hours in the air,¹¹ giving rise to amended risk assessment guidance of ventilation in healthcare settings.¹² In addition, the introduction of vaccinations have reduced emergency hospital admission of COVID-19 by 37%–43%,¹³ which will have had a significant impact on the rate of nosocomial infection during early 2021.

Over a year into this pandemic, the global community affected by COVID-19 has come a long way. Successful vaccination drives in many countries, and treatments such as dexamethasone and tocilizumab which attenuate the disease process, are proof that the efforts of the research community are fruitful. On the flipside, there is the ever-evolving threat

of COVID-19 variants and populations which may never achieve herd immunity for many reasons. For those reasons, the importance of continuing to be vigilant in order to prevent nosocomial infection remains paramount.

Contributors JC drafted the article, which all other authors edited. JC was responsible for submission.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Collins JT, Carter B, Hewitt J. *Thorax* 2021;**76**:1174–1175.

Received 7 June 2021

Accepted 14 September 2021

Published Online First 27 September 2021



► <http://dx.doi.org/10.1136/thoraxjnl-2021-216964>

Thorax 2021;**76**:1174–1175.

doi:10.1136/thoraxjnl-2021-217661

ORCID iD

Jemima T Collins <http://orcid.org/0000-0003-3865-7334>

REFERENCES

- Magill SS, Edwards JR, Bamberg W, *et al*. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med* 2014;**370**:1198–208.
- Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;**323**:1061–9.
- Ponsford MJ, Jefferies R, Davies C, *et al*. Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults. *Thorax* 2021;**76**:1246–9.
- Carter B, Collins JT, Barlow-Pay F, *et al*. Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial study (COVID in older people). *J Hosp Infect* 2020;**106**:376–84.
- CQC to ramp up inspections of trusts' infection control. Available: <https://www.pslhub.org/blogs/entry/1707-cqc-to-ramp-up-inspections-of-trusts'-infection-control/>

¹Geriatric Medicine, University Hospital of Wales Cardiff, Cardiff, UK

²Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

³Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK

Correspondence to Dr Jemima T Collins, Geriatric Medicine, University Hospital of Wales Cardiff, Cardiff CF10 3AT, UK; jemimacollins@doctors.org.uk



- 6 Illingworth CJ, Hamilton WL, Warne B, *et al.* Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections. *Elife* 2021;10:e67308.
- 7 Hewitt J, Carter B, Vilches-Moraga A, *et al.* The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. *Lancet Public Health* 2020;5:e444–51.
- 8 Collins JT, Short R, Carter B, *et al.* The clinical frailty scale: estimating the prevalence of frailty in older patients hospitalised with COVID-19. The cope study. *Geriatrics* 2020;5:58.
- 9 Vilches-Moraga A, Price A, Braude P, *et al.* Increased care at discharge from COVID-19: the association between pre-admission frailty and increased care needs after hospital discharge; a multicentre European observational cohort study. *BMC Med* 2020;18:408.
- 10 Scientific Advisory Group for Emergencies (SAGE). Contribution of nosocomial infections to the first wave, 2020. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961210/S1056_Contribution_of_nosocomial_infections_to_the_first_wave.pdf [Accessed 21 Sep 2021].
- 11 Greenhalgh T, Jimenez JL, Prather KA, *et al.* Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *Lancet* 2021;397:1603–5.
- 12 Public Health England. COVID-19 infection prevention and control guidance: key messages and explanation of updates, 2021. Available: <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/updates-to-the-infection-prevention-and-control-guidance-for-covid-19>
- 13 Lopez Bernal J, Andrews N, Gower C, *et al.* Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021;373:n1088.